<DOC>
	<DOCNO>NCT02788084</DOCNO>
	<brief_summary>1 . Develop Next-Generation Sequencing ( NGS ) workflow mutation profile formalin-fixed paraffin-embedded ( FFPE ) tissue cell-free DNA ( cfDNA ) specimens . 2 . Calculate proportion case test series B-cell non-Hodgkin Lymphomas ( BNHL ) somatic mutation immunoglobulin heavy chain ( IGH ) gene rearrangement common FPPE cfDNA specimen . 3 . Determine certain type BNHL likely mutation profile common FFPE &amp; correspond cfDNA ( `` FFPE-cfDNA dyad '' ) 4 . Determine specific mutation mutation profile FFPE cfDNA specimen ( ) prognostic value clinical follow-up 2 year time diagnosis .</brief_summary>
	<brief_title>Development Tissue-Based &amp; Cell Free DNA Next-Generation Sequencing Workflow</brief_title>
	<detailed_description>Patients newly diagnose B cell NHL identify . Samples core diagnostic FFPE block assay find lymphoma specific variant immunoglobulin heavy chain gene rearrangement . Blood sample collect baseline compare see variant rearrangement detect tumor specific DNA base previous study . Participant data collect , clinical outcome assessed determine effect mutation profile outcomes 2 year follow . Blood sample prospectively collect schedule follow primary objective study meet , assess presence cfDNA impact variation clinical outcome .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>New diagnosis B cell NHL Willing blood collect timepoints regularly schedule follow Formalin fix paraffin embed ( FFPE ) diagnostic specimen sufficient test Unwilling unable participate follow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Next Generation Sequencing</keyword>
	<keyword>Cell free DNA</keyword>
</DOC>